Even perhaps to discuss the Presidential Symposium, we have started with one analysis of screening and also tobacco cessation is really important. This message is important, that tobacco is the reason for 85% of lung cancer, so it’s important to stop. Screening, we need to work also in screening technologies even in a smoker population. Also we have discussed these studies with neoadjuvant immunotherapy, with adjuvant strategies and also with surgical techniques probably less aggressive.
So this is what we have discussed in the Presidential but also the future of early stage disease would be the analysis of circulating tumour DNA. Blood analysis determinations with technologies, with new technologies, in order to detect the minimal residual disease in the group of patients and, again, trying to treat those patients with high risk of relapse.